Reckitt Benckiser heads toward its October 23 earnings update in an unusual position: short sellers have almost entirely left the stock alone, leaving the debate about the consumer health giant's recovery squarely in the hands of fundamental investors.
The lending market tells the clearest version of this story. Availability is effectively unlimited — the 52-week low on availability has been 7,134%, meaning there are vastly more shares available to borrow than there are shorts actually borrowing them. That figure has been at or near the ceiling of measurable supply for months. Cost to borrow is running at just 0.61%, fractionally higher than a month ago but still firmly in the "free to borrow" category for most short sellers. The ORTEX short score of 37.8 ranks in the 44th percentile for short interest, and the broader positioning data confirms this is not a name attracting meaningful speculative pressure from the short side. Borrow conditions are as loose as they get.
The Street's view is more divided than the lending market suggests. Consensus sits at hold, with five hold ratings against four outperform calls. The mean price target of £62.39 compares to a current price of £50.66, implying roughly 23% upside — though with no recent analyst changes in the data, the question is whether that gap reflects genuine conviction or simply stale targets that haven't been refreshed since the stock's slide this year. Valuation multiples give a mixed read: the stock trades at 14.5x earnings and 10.4x EV/EBITDA, both drifting modestly higher over the past month as the share price has been flat to slightly lower. The EPS surprise factor score ranks in just the 15th percentile, meaning Reckitt has consistently underdelivered against forecasts — a headwind that helps explain why a double-digit implied upside hasn't attracted more buying pressure.
Insider activity adds a nuanced layer. Since June, multiple non-executive directors have bought shares in the open market — Pat Verduin, Harry Kirsch, Deepak Nath, Marybeth Hays, and most recently Deborah Waterhouse and Gavin Patterson in late August. None of the purchases are large in absolute terms, with individual transactions running to a few hundred shares at prices around £46–52. The CEO and CFO activity flagged in June was classified as "Other" rather than open-market purchases, limiting its signal value. The cumulative picture is one of board-level symbolic buying rather than aggressive conviction — directors participating in mandatory or share-plan top-ups rather than making a high-conviction call on the stock. Net insider buying across the 90-day window totals just under 5,600 shares, a rounding error relative to the company's free float.
On the institutional side, BlackRock remains the largest holder at 9.5% of shares, adding around one million shares in its most recent reported period. Causeway Capital added two million shares, a more meaningful move for a manager of that size. First Eagle also added modestly. The picture is one of value-oriented managers building slowly — consistent with the discount to price targets — rather than momentum investors rotating in on a recovery trade.
The earnings history offers some comfort for bulls. After May's print the stock fell 3.3% on the day and lost a further 1.9% over five sessions. But July's results produced a 2.4% gain that extended to 3.2% over the following week. With the next event set for October 23, the week's modest price movement — up 0.4% — suggests the market is neither anticipating a catalyst nor particularly worried about one. Close peers CL and KMB both fell 1–4% on the week while Reckitt essentially held flat, a mild relative outperformance that may reflect some defensive rotation into the name ahead of the autumn print.
What to watch between now and October 23 is whether analyst coverage starts to move — either fresh upgrades anchoring the bull case around the portfolio restructuring thesis, or target cuts that close the gap between consensus and where the stock is actually trading.
See the live data behind this article on ORTEX.
Open RKT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
